ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Veradigm Advances Deeper Clinical Insights Through NLP-Enhanced EHR Data

NLP-enhanced data from over 154 million patient records facilitates innovation in real-world evidence research via the Veradigm Network

Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today the complete integration of advanced natural language processing (NLP) into its electronic health record (EHR) dataset. This integration enhances access to valuable insights from unstructured EHR data and combines it with structured data to create regulatory-grade, real-world data (RWD) that’s purpose-built for research.

Veradigm Network EHR Data is sourced from over 154 million unique patient records and is one of the most comprehensive ambulatory databases in the United States, providing insights on a wide range of geographically and demographically diverse patients. Veradigm ensures that its NLP-enriched EHR data is standardized, de-identified, and designed to maximize research potential.

The dataset encompasses over five billion distinct patient notes sourced from multiple EHR systems and a diverse range of specialties, collected over a rolling five-year period. The unstructured data is then processed by Veradigm’s NLP models, developed by clinicians and data scientists to extract crucial clinical insights into structured data tables. Veradigm Network EHR Data seamlessly integrates with third-party datasets, offering researchers the flexibility to link and expand their analyses.

“The future of healthcare research relies on access to real-time, comprehensive data, and a significant portion of this data is unstructured,” said Stuart Green, SVP and General Manager at Veradigm. “Veradigm has invested in developing solutions that bring together disparate structured and unstructured data to provide researchers a more comprehensive understanding of the patient journey.”

These data offer valuable insights into therapy decisions, disease progression, and patient outcomes. Researchers can also leverage Veradigm’s data to support clinical trials, regulatory submissions, and safety studies.

Veradigm offers customized, high-quality data solutions to meet specific research and business needs. To learn more, contact a Veradigm representative at https://veradigm.com/contact.

About Veradigm®

Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions for the healthcare provider, payer, and biopharma markets. For more information about how Veradigm is fulfilling its mission of Transforming Health, Insightfully, visit www.veradigm.com, or find Veradigm on LinkedIn, Facebook, Twitter, Instagram, and YouTube.

© 2024 Veradigm LLC and/or its affiliates. All rights reserved. Cited marks are the property of Veradigm LLC and/or its affiliates. All other product or company names are the property of their respective holders, all rights reserved.

This integration enhances access to valuable insights from unstructured EHR data and combines it with structured data to create regulatory-grade, real-world data that’s purpose-built for research.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  244.41
+1.37 (0.56%)
AAPL  268.47
-1.30 (-0.48%)
AMD  233.54
-4.16 (-1.75%)
BAC  53.20
-0.09 (-0.17%)
GOOG  279.70
-5.64 (-1.98%)
META  621.71
+2.77 (0.45%)
MSFT  496.82
-0.28 (-0.06%)
NVDA  188.15
+0.07 (0.04%)
ORCL  239.26
-4.54 (-1.86%)
TSLA  429.52
-16.39 (-3.68%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.